Note the time zone of the Virtual Congress is Eastern Daylight Time (EDT, UTC-4)
Please use the arrow to scroll right for additional sessions
The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Virtual Platform
Session Type
Product Theater
Date
Sat, 10/23/21
Session Time
10:15 AM - 10:45 AM
Session Description
THE ONLY RECOMBINANT ERWINIA ASPARAGINASE APPROVED FOR THE TREATMENT OF ALL/LBL - Symposium supported by Jazz Pharmaceuticals Inc.
Session Description
THIS PROGRAM WILL: • Discuss the importance of asparaginase as a fundamental component of ALL treatment and the clinical impact of hypersensitivity reactions • Drive understanding of the recombinant manufacturing process and the benefits of this model • Review clinical information about this new treatment, including the study overview, dosing regimen, and safety profile
THE ONLY RECOMBINANT ERWINIA ASPARAGINASE APPROVED FOR THE TREATMENT OF ALL/LBL
Session Type
Product Theater
Date
Sat, 10/23/21
Session Time
10:15 AM - 10:45 AM
Lecture Time
10:15 AM - 10:15 AM
Supported By Jazz Pharmaceuticals
Session Type
Product Theater
Date
Sat, 10/23/21
Session Time
10:15 AM - 10:45 AM
Lecture Time
10:15 AM - 10:15 AM
THE ONLY RECOMBINANT ERWINIA ASPARAGINASE APPROVED FOR THE TREATMENT OF ALL/LBL
Session Type
Product Theater
Date
Sat, 10/23/21
Session Time
10:15 AM - 10:45 AM
Presenter
- Luke Maese (United States of America)
Lecture Time
10:15 AM - 10:40 AM
Q&A and Closing remarks
Session Type
Product Theater
Date
Sat, 10/23/21
Session Time
10:15 AM - 10:45 AM
Presenter
- Luke Maese (United States of America)
- Lindsay Geoghegan (United States of America)
Lecture Time
10:40 AM - 10:45 AM